LEADER 01830nam  2200361   450 
001 9910688469603321
005 20230624094036.0
035   $a(CKB)5400000000043604
035   $a(NjHacI)995400000000043604
035   $a(EXLCZ)995400000000043604
100   $a20230624d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGraves' Disease /$fedited by Robert Gensure
210  1$aLondon, United Kingdom :$cIntechOpen,$d2021.
215   $a1 online resource (312 pages) $cillustrations
311   $a1-83968-775-4 
330   $aGraves' disease is caused by autoantibodies to the thyroid gland that mimic thyroid-stimulating hormone, causing the gland to overproduce thyroid hormone. This speeds the metabolism of the patient and can lead to dangerous conditions including atrial fibrillation and heart failure. Mainstays of treatment have included antithyroid medication, surgical removal of the thyroid gland, and more recently, radiofrequency ablation of the thyroid gland. Advancements in diagnostic testing have enhanced our understanding of the natural course of the disease, creating additional therapeutic options. Enhanced understanding of the autoimmunity behind the disorder may lead to therapeutic options that address the underlying autoimmunity. This book provides a comprehensive review of these enhancements and how they have resulted in changes in common clinical practice.
606   $aGraves' disease
606   $aImmunology
615  0$aGraves' disease.
615  0$aImmunology.
676   $a616.4
702   $aGensure$b Robert
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688469603321
996   $aGraves' Disease$91762847
997   $aUNINA